Evidence map›Paper›PMID 40116298›Full record

ArticleProtein science : a publication of the Protein Society2025

Data-driven evaluation of suitable immunogens for improved antibody selection.

Katharina Waury, Hlin Kvartsberg, Henrik Zetterberg, Kaj Blennow, Charlotte E Teunissen, Sanne Abeln

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Data-driven evaluation of suitable immunogens for improved antibody selection.Protein science : a publication of the Protein Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Katharina WauryDepartment of Computer Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-8570-7640
Hlin KvartsbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.ORCID 0000-0002-4481-508X
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.ORCID 0000-0003-3930-4354
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.ORCID 0000-0002-1890-4193
Charlotte E TeunissenNeurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands.ORCID 0000-0002-4061-0837
Sanne AbelnDepartment of Computer Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-2779-7174

Funding

ALF-agreement ALFGBG-71320ALF-agreement ALFGBG-715986ALF-agreement ALFGBG-965240Alzheimer Drug Discovery Foundation (ADDF) 201809-2016862Alzheimerfonden AF-930351Alzheimerfonden AF-939721Alzheimerfonden AF-968270Alzheimerfonden AF-994551Alzheimer NederlandAlzheimer's Association ADSF-21-831376-CAlzheimer's Association ADSF-21-831377-CAlzheimer's Association ADSF-21-831381-CAlzheimer's Association ADSF-24-1284328-CAlzheimer's Association SG-23-1038904 QCAlzheimer's Association ZEN-21-848495Alzheimer's Disease Strategic FundEU Joint Programme - Neurodegenerative Disease Research JPND2019-466-236EU Joint Programme - Neurodegenerative Disease Research JPND2021-00694European Partnership on MetrologyFamiljen Rönströms StiftelseFondation pour la Recherche sur AlzheimerHealth∼Holland LSHM20106Hjärnfonden ALZ2022-0006Hjärnfonden FO2017-0243Hjärnfonden FO2022-0270Horizon 2020 101053962Horizon 2020 22HLT07Horizon 2020 831434Horizon 2020 860197Innovative Medicines Initiative 101034344Kirsten and Freddy Johansen FoundationNetherlands eScience CenterSwedish Research Council 2017-00915Swedish Research Council 2019-02397Swedish Research Council 2022-00732Swedish Research Council 2022-01018Swedish Research Council 2023-00356UK Dementia Research Institute UKDRI-1003ZonMw 10510032120003ZonMw 73305095007
6 · The paper itself

Abstract

Antibodies are indispensable in laboratory and clinical applications due to their high specificity and affinity for protein antigens. However, selecting the right protein fragments as immunogens for antibody production remains challenging. Leveraging the Human Protein Atlas, this study systematically evaluates immunogen properties aiming to identify key factors that influence their suitability. Antibodies were classified as successful or unsuccessful based on standardized validation experiments, and the structural and functional properties of their immunogens were analyzed. Results indicated that longer immunogens often resulted in more successful but less specific antibodies. Shorter immunogens (50 residues or fewer) with disordered or unfolded regions at the N- or C-terminus and long coil stretches were more likely to generate successful antibodies. Conversely, immunogens with high beta sheet content, transmembrane regions, or disulfide bridges were associated with poorer antibody performance. Post-translational modification sites within immunogens appeared to mark beneficial regions for antibody generation. To support antibody selection, a novel R package, immunogenViewer, was developed, enabling researchers to easily apply these insights when immunogen sequences are disclosed. By providing a deeper understanding of immunogen suitability, this study promotes the development of more effective antibodies, ultimately addressing issues of reproducibility and reliability in antibody-based research. The findings are highly relevant to the research community, as end users often lack control over the immunogen selection process in antibody production. The R package is freely available as part of Bioconductor: https://bioconductor.org/packages/release/bioc/html/immunogenViewer.html.

Indexed as

AntibodiesAntigensDatabases, ProteinHumansAntibodiesAntigensantibodyantigendisorderHuman Protein Atlasimmunogenprotein structure

Identifiers

PMID40116298
PMCPMC11926642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.